Nielsen BioSciences, Inc.
$3.3M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
LEO Pharma Inc.
LEO Pharma Inc. reported $3,298,124.04 across General Payments, Research, and Ownership to 38,155 physicians and teaching hospitals across 38,160 transactions.
- $3.3M Top quartile payer
- All-tracks total
- 38,160 Top 10% volume
- Transactions
- 38,155 Top 10% reach
- Recipients
- +$252.6K
- General Payments vs PY2023
LEO Pharma Inc. reported $3,298,124.04 across all CMS Open Payments tracks (General + Research + Ownership) to 38,155 physicians and teaching hospitals in Program Year 2024 - ranking #342 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,068,218.60, averaging $86.44 per recipient.
How LEO Pharma Inc.'s $3.3M all-tracks total breaks down
LEO Pharma Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
C
79/100
Total payments
F
40/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer leo-pharma-inc LEO Pharma Inc.
$3.3M · #342/1,925 · 0.0% industry · PY2024
- TOT $3.3M
- RANK #342
- SHARE 0.0%
- TXN 38,160
- RCP 38,155
- CAT 6
- GEN $3.1M
- ΔGEN +$252.6K
- TOP1 3.5%
- PY 2024
Volume peers
Nearest volume peer: Nielsen BioSciences, Inc. ($3.3M)
LEO Pharma Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
LEO Pharma Inc.'s CMS-reported General Payments increased by $252.6K (+9.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: LEO PHARMA INC.PY2023: LEO PHARMA INC.PY2024: LEO Pharma Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $2,815,593.69
- PY2024
- $3,068,218.60
What the Data Shows for LEO Pharma Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For LEO Pharma Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $1.1M, accounting for 36.5% of this company's General Payments and 1,084 transactions.
General Payment Breakdown by Type
Across 6 types of general payments, LEO Pharma Inc.'s largest category was "Consulting Fee" at $1.1M - 36.5% of General Payments.
LEO Pharma Inc. reports 6 general-payment categories - the top three are Consulting Fee (36.5%), Compensation for Services Other Than Consulting (32.1%), and Food and Beverage (27.6%). The remaining 3 categories make up 3.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How LEO Pharma Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.1M | 1,084 | 36.5% |
| Compensation for Services Other Than Consulting | $985.6K | 356 | 32.1% |
| Food and Beverage | $846.1K | 36,422 | 27.6% |
| Travel and Lodging | $108.2K | 233 | 3.5% |
| Space Rental or Facility Fees | $5.5K | 2 | 0.2% |
| Education | $1.4K | 58 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $438,067.14 (14.3%) of $3,068,218.60 in this company's General Payments records across 9,178 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for LEO Pharma Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Naiem Issa
$106,983.29 across 115 reported transactions
- 2
Firas Hougeir
$96,771.72 across 70 reported transactions
- 3
Adrian Rodriguez
$86,794.74 across 95 reported transactions
- 4
Leon Kircik
$77,429.13 across 16 reported transactions
- 5
Michelle Ehrlich
$70,088.26 across 81 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
LEO Pharma Inc. ranks #342 of 1,925 by total payments (top 18% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,707 of 1,838 by HHI (bottom 7% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Validus Pharmaceuticals LLC : $12.3K total payments, HHI 95
- CSL Behring : $4.9M total payments, HHI 91
- Biotissue Holdings Inc. : $2.1M total payments, HHI 90
- Kerecis Limited : $4.0M total payments, HHI 89
- Elite Orthopedics, Llc : $97.1K total payments, HHI 89
- Biosense Webster, Inc. : $3.2M total payments, HHI 89
- LEO Pharma Inc. (this company) : $3.1M total payments, HHI 88
- Medinc of Texas : $86.5K total payments, HHI 87
- Vertical Pharmaceuticals, LLC : $60.9K total payments, HHI 86
- Sight Sciences, Inc. : $1.0M total payments, HHI 85
- Astellas Pharma US Inc : $10.6M total payments, HHI 85
- Centrix Inc : $17.9K total payments, HHI 84
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as LEO Pharma Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about LEO Pharma Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with LEO Pharma Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Paratek Pharmaceuticals, Inc.
$3.3M 23,113 recipients
Compare payment profiles
Biotissue Holdings Inc.
$3.3M 20,909 recipients
Compare payment profiles
Kowa Holdings America, Inc.
$3.3M 0 recipients
Compare payment profiles
Merit Medical Systems Inc
$3.3M 1,352 recipients
Compare payment profiles
Oyster Point Pharma, Inc.
$3.3M 19,684 recipients
Compare payment profiles
Put this to use
LEO Pharma Inc. ranks #342 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where LEO Pharma Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just LEO Pharma Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.